February 17, 2026
– AgeneBio retains exclusive rights to a low-dose, extended- release formulation of levetiracetam designed exclusively for treating cognitive impairment associated with various neurodegenerative indications Baltimore, MD — February 13, 2026 — AgeneBio holds issued patents covering proprietary once-daily extended-release formulations…
August 5, 2025
AAIC Session July 30, 2025 “Network alterations and aberrant neuronal activity in Alzheimer’s disease: novel targets to understand and influence disease progression” Our presentation within this scientific session focused on AD biomarker findings in AgeneBio’s HOPE4MCI clinical trial. AgeneBio’s presentation…
October 29, 2024
https://www.medicalnewstoday.com/articles/could-a-once-daily-pill-for-seizures-also-treat-alzheimers-disease
October 17, 2024
• The Phase 2B trial showed 40% less clinical decline and significantly reduced atrophy of the entorhinal cortex, a key marker of disease progression, compared to placebo in ApoE-4 non- carriers with MCI due to AD • Patients were given…
April 23, 2024
Examining Progression in MCI Due to AD: Results from a Phase 2b Trial of AGB101 Using high resolution structural brain imaging to monitor brain atrophy as a biomarker of progression Consistent with a decrease in clinical and cognitive progression (CDR…
March 12, 2024
AGB101 for the treatment of neuropsychiatric symptoms in Parkinson’s disease Presenter: Arnold Bakker, Ph.D., Johns Hopkins University Abstract Authors: Arnold Bakker, Gregory Pontone, Richard Mohs, Michela Gallagher Poster Presentation Hippocampal hyperactivity is a pathological hallmark of Alzheimer’s disease (AD) and…
November 23, 2022
HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease with AGB101: Baseline Tau and MRI imaging characteristics Richard Mohs 1 , Sharon Rosenzweig-Lipson 1 , Arnold Bakker2 , Elizabeth Chang2 , Nisha Rani2 ,…
December 15, 2021
Overactivity in the hippocampus, likely tied to lack of inhibition, underlies some age-related cognitive decline. Targeting those circuits shows early promise in slowing memory loss. Read More: “Boosting the Brain’s Brakes to Beat Memory Loss”
August 25, 2021
Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The Hope4MCI Trial
